Yutong Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yutong Guo has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Costas Arvanitis
Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, USA
7 shared publications - Dai Fukumura
Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital and Harvard Medical School
3 shared publications - Hohyun Lee
Woodruff School of Mechanical Engineering Georgia Institute of Technology Atlanta Georgia United States
3 shared publications - Katherine W. Ferrara
Department of Radiology, Stanford University, Stanford, CA, USA
3 shared publications - Meenal Datta
Department of Aerospace and Mechanical Engineering, University of Notre Dame
3 shared publications - Miguel Oscar Bernabeu
Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh EH16 4UX, UK
3 shared publications
Latest Publications
- Open Access
Microbubble-Enhanced Focused Ultrasound Improves Targeted Adeno-Associated Virus Delivery in Brain Tumors Quantified by PET Imaging
Gene therapy using adeno-associated virus (AAV) vectors shows promise for cancer treatment through molecular intervention, yet achieving sufficient and targeted delivery to brain tumors via systemic administration remains limited by the biological barriers. Here, we investigate whether microbubble-enhanced focused ultrasound (MB-FUS) improves targeted delivery of systemically administered AAV9 to orthotopic gliomas, using quantitative PET imaging of 64 Cu-radiolabeled AAV9 vectors and fluorescent reporter expression to assess biodistribution and functional efficacy. At 21 hours after injection, 64 Cu-AAV9 accumulation was 3.2-fold higher in FUS-treated tumors compared to non-FUS-treated tumors (n=3, p=0.004). Quantitative PCR analysis of tumor tissue at the same timepoint confirmed a 6.4-fold increase in genome copies in FUS-treated tumors (p=0.0003). The enhanced vector delivery translated to a 5.3-fold increase in optical reporter protein expression in FUS-treated compared to control tumors (p=0.0002) at 17 days post-treatment. These results establish that MB-FUS enables spatially-targeted AAV delivery with quantifiable enhancement in both acute vector biodistribution and downstream transgene expression. The integration of radiolabeled AAV with PET imaging provides a non-invasive methodology for real-time assessment of vector delivery and optimization of treatment protocol for brain cancer gene therapy. Highlights: MB-FUS enables targeted systemic AAV delivery to brain tumors. MB-FUS enhanced vector delivery translates to increased transgene expression in gliomas. PET imaging of radiolabeled AAV allows non-invasive tracking of gene therapy vectors. Real-time imaging validates spatially-controlled gene delivery for brain cancer.
Open AccessMicrobubble-Enhanced Focused Ultrasound Improves Targeted Adeno-Associated Virus Delivery in Brain Tumors Quantified by PET Imaging
Gene therapy using adeno-associated virus (AAV) vectors shows promise for cancer treatment through molecular intervention, yet achieving sufficient and targeted delivery to brain tumors via systemic administration remains limited by the biological barriers. Here, we investigate whether microbubble-enhanced focused ultrasound (MB-FUS) improves targeted delivery of systemically administered AAV9 to orthotopic gliomas, using quantitative PET imaging of 64 Cu-radiolabeled AAV9 vectors and fluorescent reporter expression to assess biodistribution and functional efficacy. At 21 hours after injection, 64 Cu-AAV9 accumulation was 3.2-fold higher in FUS-treated tumors compared to non-FUS-treated tumors (n=3, p=0.004). Quantitative PCR analysis of tumor tissue at the same timepoint confirmed a 6.4-fold increase in genome copies in FUS-treated tumors (p=0.0003). The enhanced vector delivery translated to a 5.3-fold increase in optical reporter protein expression in FUS-treated compared to control tumors (p=0.0002) at 17 days post-treatment. These results establish that MB-FUS enables spatially-targeted AAV delivery with quantifiable enhancement in both acute vector biodistribution and downstream transgene expression. The integration of radiolabeled AAV with PET imaging provides a non-invasive methodology for real-time assessment of vector delivery and optimization of treatment protocol for brain cancer gene therapy. Highlights: MB-FUS enables targeted systemic AAV delivery to brain tumors. MB-FUS enhanced vector delivery translates to increased transgene expression in gliomas. PET imaging of radiolabeled AAV allows non-invasive tracking of gene therapy vectors. Real-time imaging validates spatially-controlled gene delivery for brain cancer.
- Open Access
Ultrasound-Mediated Gene Therapy in Alzheimer's Disease Validated through In Vivo PET Imaging
Efficient, spatially selective delivery of adeno-associated virus (AAV) therapeutics to deep brain structures remains a major challenge to gene therapy for Alzheimer's disease (AD), owing to limited transport across the blood-brain barrier (BBB) and poor penetration to target neurons. Here, we establish an integrated, noninvasive imaging and therapy platform that combines microbubble-enhanced focused ultrasound (MB-FUS) with positron emission tomography/computed tomography (PET/CT) to transiently modulate the BBB, enhance region-specific AAV delivery following systemic dosing, and longitudinally track transduction in vivo. Optimized MB-FUS achieved targeted hippocampal delivery of systemically administered AAV9 in healthy mice, resulting in a 10-fold enhancement of neuronal transduction as compared to non-FUS controls. Importantly, longitudinal PET reporter gene imaging in the 5xFAD AD model demonstrated robust brain AAV transduction that remained stable for at least seven months. Finally, to assess therapeutic impact, we used brain-derived neurotrophic factor (BDNF) as a test cargo. MB-FUS-facilitated delivery elevated BDNF expression in targeted regions and produced short-term improvements in synaptic signaling in 5xFAD mice. Collectively, these results highlight MB-FUS as a next-generation delivery platform to overcome barriers to AAV therapeutic delivery in Alzheimer's disease and position longitudinal PET assessment as a critical, translatable tool for monitoring and optimizing gene therapy.
Open AccessUltrasound-Mediated Gene Therapy in Alzheimer's Disease Validated through In Vivo PET Imaging
Efficient, spatially selective delivery of adeno-associated virus (AAV) therapeutics to deep brain structures remains a major challenge to gene therapy for Alzheimer's disease (AD), owing to limited transport across the blood-brain barrier (BBB) and poor penetration to target neurons. Here, we establish an integrated, noninvasive imaging and therapy platform that combines microbubble-enhanced focused ultrasound (MB-FUS) with positron emission tomography/computed tomography (PET/CT) to transiently modulate the BBB, enhance region-specific AAV delivery following systemic dosing, and longitudinally track transduction in vivo. Optimized MB-FUS achieved targeted hippocampal delivery of systemically administered AAV9 in healthy mice, resulting in a 10-fold enhancement of neuronal transduction as compared to non-FUS controls. Importantly, longitudinal PET reporter gene imaging in the 5xFAD AD model demonstrated robust brain AAV transduction that remained stable for at least seven months. Finally, to assess therapeutic impact, we used brain-derived neurotrophic factor (BDNF) as a test cargo. MB-FUS-facilitated delivery elevated BDNF expression in targeted regions and produced short-term improvements in synaptic signaling in 5xFAD mice. Collectively, these results highlight MB-FUS as a next-generation delivery platform to overcome barriers to AAV therapeutic delivery in Alzheimer's disease and position longitudinal PET assessment as a critical, translatable tool for monitoring and optimizing gene therapy.
- Open Access
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadw2601
Improving real-time ultrasound spine imaging with a large-aperture array
Ultrasound offers a safe, low-cost alternative to computed tomography (CT) and magnetic resonance imaging for spinal diagnostics and intervention by enabling real-time imaging. However, the complex structure of the spine and acoustic shadowing from bones present challenges for ultrasonography. This study addresses these limitations using an 8.8-centimeter 384-element large-aperture array and full aperture-based imaging protocols. Volumetric scanning across multiple vertebrae was accomplished in 5 seconds using ultrafast, diverging wave acquisition. In seven healthy volunteers, the large-aperture array and diverging wave transmission improved resolution, contrast, and visualization of the spinal canal, venous plexuses, and facet joints compared with conventional probes. A comparison between the coregistered CT and ultrasound scan confirmed the imaging accuracy. A simulated lumbar puncture demonstrated needle tip visualization throughout the trajectory into the spinal canal. The results suggest that large-aperture arrays, coupled with diverging wave imaging sequences, are a valuable tool for spine imaging and image-guided intervention.
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadw2601
Open AccessImproving real-time ultrasound spine imaging with a large-aperture array
Ultrasound offers a safe, low-cost alternative to computed tomography (CT) and magnetic resonance imaging for spinal diagnostics and intervention by enabling real-time imaging. However, the complex structure of the spine and acoustic shadowing from bones present challenges for ultrasonography. This study addresses these limitations using an 8.8-centimeter 384-element large-aperture array and full aperture-based imaging protocols. Volumetric scanning across multiple vertebrae was accomplished in 5 seconds using ultrafast, diverging wave acquisition. In seven healthy volunteers, the large-aperture array and diverging wave transmission improved resolution, contrast, and visualization of the spinal canal, venous plexuses, and facet joints compared with conventional probes. A comparison between the coregistered CT and ultrasound scan confirmed the imaging accuracy. A simulated lumbar puncture demonstrated needle tip visualization throughout the trajectory into the spinal canal. The results suggest that large-aperture arrays, coupled with diverging wave imaging sequences, are a valuable tool for spine imaging and image-guided intervention.
- Open Access
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eadd2288
Spatially targeted brain cancer immunotherapy with closed-loop controlled focused ultrasound and immune checkpoint blockade
Despite the challenges in treating glioblastomas (GBMs) with immune adjuvants, increasing evidence suggests that targeting the immune cells within the tumor microenvironment (TME) can lead to improved responses. Here, we present a closed-loop controlled, microbubble-enhanced focused ultrasound (MB-FUS) system and test its abilities to safely and effectively treat GBMs using immune checkpoint blockade. The proposed system can fine-tune the exposure settings to promote MB acoustic emission–dependent expression of the proinflammatory marker ICAM-1 and delivery of anti-PD1 in a mouse model of GBM. In addition to enhanced interaction of proinflammatory macrophages within the PD1-expressing TME and significant improvement in survival ( P < 0.05), the combined treatment induced long-lived memory T cell formation within the brain that supported tumor rejection in rechallenge experiments. Collectively, our findings demonstrate the ability of MB-FUS to augment the therapeutic impact of immune checkpoint blockade in GBMs and reinforce the notion of spatially tumor-targeted (loco-regional) brain cancer immunotherapy.
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eadd2288
Open AccessSpatially targeted brain cancer immunotherapy with closed-loop controlled focused ultrasound and immune checkpoint blockade
Despite the challenges in treating glioblastomas (GBMs) with immune adjuvants, increasing evidence suggests that targeting the immune cells within the tumor microenvironment (TME) can lead to improved responses. Here, we present a closed-loop controlled, microbubble-enhanced focused ultrasound (MB-FUS) system and test its abilities to safely and effectively treat GBMs using immune checkpoint blockade. The proposed system can fine-tune the exposure settings to promote MB acoustic emission–dependent expression of the proinflammatory marker ICAM-1 and delivery of anti-PD1 in a mouse model of GBM. In addition to enhanced interaction of proinflammatory macrophages within the PD1-expressing TME and significant improvement in survival ( P < 0.05), the combined treatment induced long-lived memory T cell formation within the brain that supported tumor rejection in rechallenge experiments. Collectively, our findings demonstrate the ability of MB-FUS to augment the therapeutic impact of immune checkpoint blockade in GBMs and reinforce the notion of spatially tumor-targeted (loco-regional) brain cancer immunotherapy.
- 18 November 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 180, 114043
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound
- 18 November 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 180, 114043
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound
- Top Cited Papers
- 9 September 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (37)
Localized blood–brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions–controlled focused ultrasound
Pharmacological treatment of gliomas and other brain-infiltrating tumors remains challenging due to limited delivery of most therapeutics across the blood–brain barrier (BBB). Transcranial MRI-guided focused ultrasound (FUS), an emerging technology for noninvasive brain treatments, enables transient opening of the BBB through acoustic activation of circulating microbubbles. Here, we evaluate the safety and utility of transcranial microbubble-enhanced FUS (MB-FUS) for spatially targeted BBB opening in patients with infiltrating gliomas. In this Phase 0 clinical trial (NCT03322813), we conducted comparative and quantitative analyses of FUS exposures (sonications) and their effects on gliomas using MRI, histopathology, microbubble acoustic emissions (harmonic dose [HD]), and fluorescence-guided surgery metrics. Contrast-enhanced MRI and histopathology indicated safe and reproducible BBB opening in all patients. These observations occurred using a power cycling closed feedback loop controller, with the power varying by nearly an order of magnitude on average. This range underscores the need for monitoring and titrating the exposure on a patient-by-patient basis. We found a positive correlation between microbubble acoustic emissions (HD) and MR-evident BBB opening (P = 0.07) and associated interstitial changes (P < 0.01), demonstrating the unique capability to titrate the MB-FUS effects in gliomas. Importantly, we identified a 2.2-fold increase of fluorescein accumulation in MB-FUS–treated compared to untreated nonenhancing tumor tissues (P < 0.01) while accounting for vascular density. Collectively, this study demonstrates the capabilities of MB-FUS for safe, localized, controlled BBB opening and highlights the potential of this technology to improve the surgical and pharmacologic treatment of brain tumors. Significance The blood–brain barrier (BBB) is a critical obstacle to delivering most therapeutics into the brain. In this study, we report combined MRI, histological, and real-time acoustic emissions monitoring findings from a Phase 0 clinical trial examining microbubble-enhanced transcranial focused ultrasound for controlled BBB opening in patients with infiltrating gliomas. The data revealed the capability of this technology to provide safe, controlled, and tightly monitored BBB opening through the intact skull. Our findings demonstrate the capability of this technology to tune BBB opening in real-time, creating opportunities for improved treatment of brain tumors.
- 9 September 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (37)
Top Cited PapersLocalized blood–brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions–controlled focused ultrasound
Pharmacological treatment of gliomas and other brain-infiltrating tumors remains challenging due to limited delivery of most therapeutics across the blood–brain barrier (BBB). Transcranial MRI-guided focused ultrasound (FUS), an emerging technology for noninvasive brain treatments, enables transient opening of the BBB through acoustic activation of circulating microbubbles. Here, we evaluate the safety and utility of transcranial microbubble-enhanced FUS (MB-FUS) for spatially targeted BBB opening in patients with infiltrating gliomas. In this Phase 0 clinical trial (NCT03322813), we conducted comparative and quantitative analyses of FUS exposures (sonications) and their effects on gliomas using MRI, histopathology, microbubble acoustic emissions (harmonic dose [HD]), and fluorescence-guided surgery metrics. Contrast-enhanced MRI and histopathology indicated safe and reproducible BBB opening in all patients. These observations occurred using a power cycling closed feedback loop controller, with the power varying by nearly an order of magnitude on average. This range underscores the need for monitoring and titrating the exposure on a patient-by-patient basis. We found a positive correlation between microbubble acoustic emissions (HD) and MR-evident BBB opening (P = 0.07) and associated interstitial changes (P < 0.01), demonstrating the unique capability to titrate the MB-FUS effects in gliomas. Importantly, we identified a 2.2-fold increase of fluorescein accumulation in MB-FUS–treated compared to untreated nonenhancing tumor tissues (P < 0.01) while accounting for vascular density. Collectively, this study demonstrates the capabilities of MB-FUS for safe, localized, controlled BBB opening and highlights the potential of this technology to improve the surgical and pharmacologic treatment of brain tumors. Significance The blood–brain barrier (BBB) is a critical obstacle to delivering most therapeutics into the brain. In this study, we report combined MRI, histological, and real-time acoustic emissions monitoring findings from a Phase 0 clinical trial examining microbubble-enhanced transcranial focused ultrasound for controlled BBB opening in patients with infiltrating gliomas. The data revealed the capability of this technology to provide safe, controlled, and tightly monitored BBB opening through the intact skull. Our findings demonstrate the capability of this technology to tune BBB opening in real-time, creating opportunities for improved treatment of brain tumors.
- Open Access
- 30 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (18) , eabf7390
Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles
RNA-based therapies offer unique advantages for treating brain tumors. However, tumor penetrance and uptake are hampered by RNA therapeutic size, charge, and need to be “packaged” in large carriers to improve bioavailability. Here, we have examined delivery of siRNA, packaged in 50-nm cationic lipid-polymer hybrid nanoparticles (LPHs:siRNA), combined with microbubble-enhanced focused ultrasound (MB-FUS) in pediatric and adult preclinical brain tumor models. Using single-cell image analysis, we show that MB-FUS in combination with LPHs:siRNA leads to more than 10-fold improvement in siRNA delivery into brain tumor microenvironments of the two models. MB-FUS delivery of Smoothened (SMO) targeting siRNAs reduces SMO protein production and markedly increases tumor cell death in the SMO-activated medulloblastoma model. Moreover, our analysis reveals that MB-FUS and nanoparticle properties can be optimized to maximize delivery in the brain tumor microenvironment, thereby serving as a platform for developing next-generation tunable delivery systems for RNA-based therapy in brain tumors.
- 30 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (18) , eabf7390
Open AccessSingle-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles
RNA-based therapies offer unique advantages for treating brain tumors. However, tumor penetrance and uptake are hampered by RNA therapeutic size, charge, and need to be “packaged” in large carriers to improve bioavailability. Here, we have examined delivery of siRNA, packaged in 50-nm cationic lipid-polymer hybrid nanoparticles (LPHs:siRNA), combined with microbubble-enhanced focused ultrasound (MB-FUS) in pediatric and adult preclinical brain tumor models. Using single-cell image analysis, we show that MB-FUS in combination with LPHs:siRNA leads to more than 10-fold improvement in siRNA delivery into brain tumor microenvironments of the two models. MB-FUS delivery of Smoothened (SMO) targeting siRNAs reduces SMO protein production and markedly increases tumor cell death in the SMO-activated medulloblastoma model. Moreover, our analysis reveals that MB-FUS and nanoparticle properties can be optimized to maximize delivery in the brain tumor microenvironment, thereby serving as a platform for developing next-generation tunable delivery systems for RNA-based therapy in brain tumors.
- 22 October 2019
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (3) , 1098-1102
A Photowelding Strategy for Conductivity Restoration in Flexible Circuits
Light‐driven micropumps, which are based on electro‐osmosis with the electric field generated by photocatalytic reactions, are among most attractive research topics in chemical micromotors. Until now, research in this field has mainly been focused on the directional motion or collective behavior of microparticles, which lack practical applications. In this study, we have developed a photowelding strategy for repeated photoinduced conductivity recovery of cracked flexible circuits. We immersed the circuit in a suspension of conductive healing particles and applied photoillumination to the crack; photocatalysis of a predeposited pentacene (PEN) layer triggered electro‐osmotic effects to gather conductive particles at the crack, thus leading to conductivity recovery of the circuit. This photowelding strategy is a novel application of light‐driven micropumps and photocatalysis for conductivity restoration.
- 22 October 2019
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (3) , 1098-1102
A Photowelding Strategy for Conductivity Restoration in Flexible Circuits
Light‐driven micropumps, which are based on electro‐osmosis with the electric field generated by photocatalytic reactions, are among most attractive research topics in chemical micromotors. Until now, research in this field has mainly been focused on the directional motion or collective behavior of microparticles, which lack practical applications. In this study, we have developed a photowelding strategy for repeated photoinduced conductivity recovery of cracked flexible circuits. We immersed the circuit in a suspension of conductive healing particles and applied photoillumination to the crack; photocatalysis of a predeposited pentacene (PEN) layer triggered electro‐osmotic effects to gather conductive particles at the crack, thus leading to conductivity recovery of the circuit. This photowelding strategy is a novel application of light‐driven micropumps and photocatalysis for conductivity restoration.
- Open Access
- 12 August 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 1 (Supplement) , i2
BSCI-09. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN METASTASES WITH FOCUSED ULTRASOUND-INDUCED BLOOD-TUMOR BARRIER DISRUPTION
Blood-brain/blood-tumor barriers (BBB and BTB) and interstitial transport may constitute major obstacles to the transport of therapeutics in brain tumors. In this study, we examined the impact of focused ultrasound (FUS) in combination with microbubbles on the transport of two relevant chemotherapy-based anticancer agents in HER2-positive breast cancer brain metastases at cellular resolution: the non-targeted chemotherapeutic doxorubicin and the antibody-drug conjugate ado- trastuzumab emtansine (T-DM1). Using an orthotopic xenograft model of HER2-positive breast cancer brain metastasis and quantitative microscopy we demonstrate multifold increases in the extravasation of both agents (7-fold and 2-fold for doxorubicin and T-DM1, respectively) and we provide evidence of increased drug penetration (>100μm vs. < 20μm and 42±7μm vs. 12±4μm for doxorubicin and T-DM1, respectively) after application of FUS as compared to control (non-FUS). Integration of experimental data with physiologically based pharmacokinetic (PBPK) modeling of drug transport reveals that FUS in combination with microbubbles alleviates vascular barriers and enhances interstitial convective transport via increase in hydraulic conductivity. Combination of experimental data and PBPK modeling suggests that FUS in combination with microbubbles increases the endothelial cell transmembrane transport and uptake. PBPK modelling indicates selective increase in transvascular transport of the non- targeted small chemotherapeutic doxorubicin through small vessel-wall pores size with a narrow range (Diameter: 10-50nm). Our work provides a quantitative framework for the optimization of FUS-drug combinations to maximize intratumoral drug delivery and facilitate the development of novel therapeutic strategies against brain metastases.
- 12 August 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 1 (Supplement) , i2
Open AccessBSCI-09. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN METASTASES WITH FOCUSED ULTRASOUND-INDUCED BLOOD-TUMOR BARRIER DISRUPTION
Blood-brain/blood-tumor barriers (BBB and BTB) and interstitial transport may constitute major obstacles to the transport of therapeutics in brain tumors. In this study, we examined the impact of focused ultrasound (FUS) in combination with microbubbles on the transport of two relevant chemotherapy-based anticancer agents in HER2-positive breast cancer brain metastases at cellular resolution: the non-targeted chemotherapeutic doxorubicin and the antibody-drug conjugate ado- trastuzumab emtansine (T-DM1). Using an orthotopic xenograft model of HER2-positive breast cancer brain metastasis and quantitative microscopy we demonstrate multifold increases in the extravasation of both agents (7-fold and 2-fold for doxorubicin and T-DM1, respectively) and we provide evidence of increased drug penetration (>100μm vs. < 20μm and 42±7μm vs. 12±4μm for doxorubicin and T-DM1, respectively) after application of FUS as compared to control (non-FUS). Integration of experimental data with physiologically based pharmacokinetic (PBPK) modeling of drug transport reveals that FUS in combination with microbubbles alleviates vascular barriers and enhances interstitial convective transport via increase in hydraulic conductivity. Combination of experimental data and PBPK modeling suggests that FUS in combination with microbubbles increases the endothelial cell transmembrane transport and uptake. PBPK modelling indicates selective increase in transvascular transport of the non- targeted small chemotherapeutic doxorubicin through small vessel-wall pores size with a narrow range (Diameter: 10-50nm). Our work provides a quantitative framework for the optimization of FUS-drug combinations to maximize intratumoral drug delivery and facilitate the development of novel therapeutic strategies against brain metastases.
- Open Access
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi281
CADD-32. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN TUMORS WITH FOCUSED ULTRASOUND-INDUCED TRANSIENT BLOOD-TUMOR BARRIER DISRUPTION
Blood-brain/blood-tumor barriers (BBB and BTB) and interstitial transport may constitute major obstacles to the transport of therapeutics in brain tumors. In this study, we examined the impact of focused ultrasound (FUS) in combination with microbubbles on the transport of two relevant chemotherapy-based anticancer agents in HER2-positive breast cancer brain metastases at cellular resolution: doxorubicin, a non-targeted low molecular weight chemotherapeutic, and ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate. Using an orthotopic xenograft model of HER2-positive breast cancer brain metastasis and quantitative microscopy we demonstrate significant increases in the extravasation of both agents (7-fold and 2-fold for doxorubicin and T-DM1, respectively) and we provide evidence of increased drug penetration (>100µm vs. <20µm and 42 ± 7µm vs. 12 ± 4µm for doxorubicin and T-DM1, respectively) after application of FUS as compared to control (non-FUS). Integration of experimental data with physiologically based pharmacokinetic (PBPK) modeling of drug transport reveals that FUS in combination with microbubbles alleviates vascular barriers and enhances interstitial convective transport via an increase in hydraulic conductivity. Combination of experimental data and PBPK modeling suggests that FUS in combination with microbubbles increases the endothelial cell transmembrane transport and uptake. PBPK modeling indicates a selective increase in transvascular transport of doxorubicin through small vessel-wall pores size with a narrow range (Diameter: 10-50nm). Our work provides a quantitative framework for the optimization of FUS-drug combinations to maximize intratumoral drug delivery and facilitate the development of novel strategies to treat brain metastases.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi281
Open AccessCADD-32. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN TUMORS WITH FOCUSED ULTRASOUND-INDUCED TRANSIENT BLOOD-TUMOR BARRIER DISRUPTION
Blood-brain/blood-tumor barriers (BBB and BTB) and interstitial transport may constitute major obstacles to the transport of therapeutics in brain tumors. In this study, we examined the impact of focused ultrasound (FUS) in combination with microbubbles on the transport of two relevant chemotherapy-based anticancer agents in HER2-positive breast cancer brain metastases at cellular resolution: doxorubicin, a non-targeted low molecular weight chemotherapeutic, and ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate. Using an orthotopic xenograft model of HER2-positive breast cancer brain metastasis and quantitative microscopy we demonstrate significant increases in the extravasation of both agents (7-fold and 2-fold for doxorubicin and T-DM1, respectively) and we provide evidence of increased drug penetration (>100µm vs. <20µm and 42 ± 7µm vs. 12 ± 4µm for doxorubicin and T-DM1, respectively) after application of FUS as compared to control (non-FUS). Integration of experimental data with physiologically based pharmacokinetic (PBPK) modeling of drug transport reveals that FUS in combination with microbubbles alleviates vascular barriers and enhances interstitial convective transport via an increase in hydraulic conductivity. Combination of experimental data and PBPK modeling suggests that FUS in combination with microbubbles increases the endothelial cell transmembrane transport and uptake. PBPK modeling indicates a selective increase in transvascular transport of doxorubicin through small vessel-wall pores size with a narrow range (Diameter: 10-50nm). Our work provides a quantitative framework for the optimization of FUS-drug combinations to maximize intratumoral drug delivery and facilitate the development of novel strategies to treat brain metastases.